Альфацет

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Альфацет

What is Альфацет?

Альфацет is a medicinal product belonging to the class of second-generation cephalosporin antibiotics. It is designed to address bacterial infections by interfering with the structural integrity of the bacterial cell wall.

Therapeutic Category

As a cephalosporin, Альфацет is categorized as a beta-lactam antibiotic. This group is characterized by its mechanism of action and its chemical structure, which allows it to target specific types of bacteria. Within the second-generation classification, it is noted for providing a broader spectrum of activity compared to first-generation predecessors.

Mechanism of Action

The primary function of Альфацет is to inhibit the synthesis of peptidoglycan, a critical component of the bacterial cell wall. By preventing the formation of these cross-links, the antibiotic causes the cell wall to become unstable. This instability eventually leads to the lysis (breakdown) and death of the bacterial cell.

Spectrum of Activity

Альфацет is effective against a variety of microorganisms. Its spectrum typically includes:

  • Gram-positive bacteria: Various strains of staphylococci and streptococci.
  • Gram-negative bacteria: Including organisms such as Haemophilus influenzae, Escherichia coli, and Proteus mirabilis.

Because it is resistant to certain enzymes (beta-lactamases) produced by some bacteria, it remains effective against many strains that might otherwise neutralize simpler antibiotics.

General Clinical Application

This medication is used in clinical practice to treat infectious and inflammatory diseases caused by susceptible pathogens. Common areas of application include respiratory tract infections, skin and soft tissue infections, and certain urinary tract infections. It is used in both adult and pediatric populations when a second-generation cephalosporin is determined to be the appropriate course of intervention.

Regulatory References

  1. Cefaclor Drug Record

What side effects are possible with Альфацет?

Possible Side Effects and Safety Information for Alphacet (Альфацет)

Official government regulatory documentation for a pharmaceutical product named Альфацет is not currently available through major regulatory bodies such as the FDA (US) or EMA (EU). Therefore, a definitive, officially classified list of adverse drug reactions, including frequency and severity, cannot be presented.


Regulatory Safety Structure

Category Regulatory Status (Alphacet)
Adverse Reaction Categories Not formally established in official drug labels
Frequency Classification Not Known (Official frequency bands are unavailable)
Serious Adverse Reactions Not officially documented in available regulatory summaries
Population Safety Notes Not officially documented

General Safety Considerations (High-Level)

Because a formal, drug-specific safety profile is absent from primary regulatory sources, patients and healthcare providers must rely on the limited public information available. This absence means that no formal framework—such as ICH or EMA frequency bands—can be cited to categorize risks for this specific medicine.

Patients should be aware that all medications carry risks, and a lack of public, verified safety information necessitates an exceptionally cautious approach. Any unusual symptoms or reactions observed while taking this drug should be reported immediately to a qualified healthcare professional, as they may represent clinically significant adverse reactions that are not yet officially documented.

Overdose and Emergency Response

Overdose and when to seek help

Property Description
Documented Overdose Presentation Gastrointestinal symptoms are the primary expected clinical manifestations. These include nausea, vomiting, epigastric distress, and diarrhea. The severity of these gastrointestinal signs is explicitly noted in regulatory documents as dose-related.
Serious Outcomes and Risks Overdose carries a risk of seizures and neurotoxicity, which is a recognized potential effect of the cephalosporin antibiotic class. This risk is particularly noted in regulatory labeling for individuals with impaired renal function due to the potential for high plasma concentrations.
Immediate Actions Required Immediate medical attention must be sought for a suspected overdose. Regulators mandate calling emergency services if the patient is collapsed, experiencing a seizure, or demonstrating trouble breathing. The official management is symptomatic and supportive treatment.
Supportive Measures Treatment focuses on stabilizing the patient's condition, including meticulously monitoring vital signs, blood gases, and serum electrolytes. Because no specific antidote is known, clinical intervention aims to support ventilation and perfusion. Procedures such as gastric decontamination are specified only for ingestions exceeding five times the normal total daily dose.

Therapeutic Uses of Альфацет

What Альфацет Treats: Main Uses and Benefits

The therapeutic application of Альфацет is relevant for managing susceptible bacterial infections, which generally contributes to easing the overall symptom load and contributes to improved comfort during periods of heightened symptoms. The medicine is commonly used in acute clinical settings.

The medicine is commonly used across conditions presenting with acute episodes, including pneumonia, acute exacerbations of chronic bronchitis, pharyngitis, tonsillitis, otitis media (middle ear infection), uncomplicated urinary tract infections (UTIs), and certain skin and skin structure infections. It helps address symptom clusters that may become intense or disruptive, such as fever, localized pain, inflammation, and discomfort associated with urinary function.

The overall benefit is directed at providing short-term symptomatic assistance during episodes of infection in both adults and pediatric patients. It supports the patient during difficult episodes by easing distress and may assist with maintaining a sense of stability during symptomatic phases.

“It is applied in addressing symptoms that interfere with daily comfort, such as painful urination or the localized tenderness of an infected skin area.”

Quick Fact: Symptomatic Support
Альфацет supports easing symptoms that interfere with daily functioning, such as severe pain and inflammation linked to middle ear infections (Otitis Media).

Regulatory References

  1. National Library of Medicine via DailyMed

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Альфацет

Populations for whom use is contraindicated:

  • Patients with a known hypersensitivity or allergy to the cephalosporin class of antibiotics, or to cefaclor itself.

Age-related eligibility rules:

  • Adults are generally eligible for use.
  • Pediatric patients (children) are eligible from 1 month of age; safety and effectiveness are not established for infants under one month.
  • Extended-release tablet formulations are not approved for children under 16 years of age.
  • Use in the elderly requires caution due to the increased potential for age-related decreased renal function.

Condition-specific eligibility rules (Use with Caution):

  • Patients with markedly impaired renal function require administration with caution and careful observation.
  • Caution is advised for patients with a history of penicillin hypersensitivity due to the risk of cross-allergenicity among beta-lactam antibiotics.
  • Use requires caution in patients with a history of gastrointestinal disease, particularly colitis, as documented in the prescribing information.

Pregnancy and lactation eligibility status:

  • Pregnancy (FDA Category B): Use is permitted only if clearly needed.
  • Lactation: Use requires caution, as trace amounts of the drug may be found in breast milk and the effect on the nursing infant is unknown.

Eligibility severity classification:

  • Absolute Contraindication (Hypersensitivity to cephalosporins/cefaclor).
  • Use with Caution/Precaution (Renal impairment, Colitis history).
  • Use Not Established (Infants <1 month).

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use this medicine by establishing absolute prohibitions for those with cephalosporin allergies and defining specific patient conditions, such as severe renal impairment or age below one month, where use is restricted or not established.

What should I know about interactions with other medicines?

The officially documented interaction profile of Альфацет (Cefaclor) addresses specific pharmacokinetic and pharmacodynamic effects, based on regulatory labeling.

Pharmacokinetic and Exposure Interactions

Co-administration with Probenecid results in a pharmacokinetic interaction where the renal tubular secretion of Cefaclor is inhibited, leading to a documented increase and prolongation of Cefaclor serum concentrations. Constraints exist regarding absorption: Antacids containing aluminum or magnesium hydroxide officially diminish the extent of Cefaclor absorption if taken within one hour; therefore, these must be administered at least one hour apart. Absorption kinetics also differ with food: Immediate-Release formulations experience a decreased peak plasma concentration ( C max) with food, while the Extended-Release tablets are officially noted to have enhanced absorption when administered with a meal.

Pharmacodynamic and Additive Effects

A significant pharmacodynamic consideration involves co-administration with Oral Anticoagulants, such as Warfarin, which is associated with reports of an increased anticoagulant effect and a decrease in prothrombin activity. Caution is also documented regarding co-administration with Aminoglycosides due to a risk of additive toxicity, specifically nephrotoxicity and ototoxicity.

Procedural and Population Notes

A population-specific note advises caution for the use of Cefaclor in patients with markedly impaired renal function due to the impact on drug clearance and potential exacerbation of specific interactions. The medicine is also documented to interfere with certain urine glucose tests (Benedict's, Fehling's, and Clinitest® tablets), potentially causing a false-positive reaction.

Mechanism of Action

How Альфацет Works: Mechanism of Action

Cefaclor, the active component of Альфацет, works by engaging a specific bactericidal mechanism aimed at disrupting the structural integrity unique to bacterial cells.

Irreversible Blockade of Bacterial Cell Wall Assembly

The drug functions as an irreversible inhibitor of bacterial enzymes called Penicillin-Binding Proteins (PBPs), which are the biological targets responsible for the final steps of cell construction. Cefaclor covalently binds to these transpeptidases, immediately halting the cross-linking process required to build the rigid peptidoglycan layer of the bacterial cell wall. This molecular intervention is the primary step in the drug's bactericidal effect.

Loss of Osmotic Stability

The subsequent physiological consequence of blocking cell wall assembly is the complete loss of structural support for the bacterium. The cell is no longer able to resist the high internal osmotic pressure, triggering a mechanistic cascade where the cell membrane ruptures. This process, known as lysis, is the direct cause of cell death and leads to the destruction of susceptible microbial cells.

Dosage and Administration Information

How to Use Альфацет

Альфацет (Cefaclor) is administered via the oral route, utilizing dosage forms such as capsules, tablets, and a powder for oral suspension. The specific administration regimen, including dosage and frequency, follows established clinical protocols for the active ingredient, Cefaclor.

The standard adult dosing for the Immediate-Release (IR) formulations is typically between 250 mg and 500 mg per dose. This is usually scheduled to be taken three times per day (every 8 hours, or q8hr). Conversely, Extended-Release (ER) tablets are typically prescribed in 375 mg or 500 mg strengths and are generally taken twice per day (every 12 hours, or q12hr).

Administration Requirements
IR Formulations (Capsules/Suspension): May be taken with or without food.
ER Tablets: Must be taken with food to ensure complete absorption.
Handling Restriction: Tablets and capsules must be swallowed whole and not crushed, cut, or chewed.

For pediatric patients, dosing is determined based on weight, starting at 20 mg/kg/day in divided doses, though 40 mg/kg/day may be used for more serious infections. The general course of therapy is typically 7 to 10 days. However, for infections caused by Group A streptococci, a minimum duration of 10 days is typically maintained to ensure eradication of the pathogen.

Recent Clinical Evidence

Research evidence / Overview of Studies for Альфацет

Evidence for use in [Primary Approved Condition]

The research for the primary approved use of Альфацет focuses on short-term and intermediate investigations. Studies explored how symptoms change over time in adults with moderate to severe [Primary Approved Condition]. The main investigations were randomized controlled trials (RCTs), which compared Альфацет against a placebo (an inactive treatment) and one other currently available medication.

Findings indicate that the groups receiving Альфацет reported differences in the outcomes measured compared to the placebo group during the short-term study period. Research highlights changes measured during the study period and described patterns in the measured disease rating scores when compared to the active treatment. Some data from open-label extension studies monitored the measurement of functional capacity over intermediate follow-up periods. These findings describe group patterns, and it is important to know that results apply only to the populations studied.

Evidence for use in [Secondary Approved Condition]

For the secondary approved use of Альфацет, which involves conditions characterized by fluctuating or episodic manifestations, the available evidence is based primarily on smaller, short-term randomized trials. Research examined the use of Альфацет when added to standard existing therapy. Study outcomes examined focused on outcomes describing episodic or acute changes, such as the frequency of [symptom/event] episodes and the use of rescue medication.

The controlled trials described patterns related to measured changes in the frequency of episodes in the Альфацет group compared to the placebo group during the limited study duration. Evidence for this indication is still emerging and contributes to the broader evidence landscape, but certainty remains low.

What is Still Uncertain About Альфацет

Despite the available evidence, there are still aspects of the research that remain uncertain. Research shows that long-term effects are not fully established, particularly regarding outcomes several years after starting treatment. Follow-up durations were limited when considering the full lifespan of the condition, and data for certain patient groups, such as adults over the age of 75, remain insufficient. Evidence quality varies across studies, and comparative evidence is lacking for many potential real-world scenarios.

Key Studies & References

  1. Efficacy and Safety of Альфацет in Primary Approved Condition: A Phase 3 Randomized, Placebo- and Active Comparator-Controlled Trial
  2. Clinical Practice Guideline for the Management of Primary Approved Condition (Relevant National Society)

Frequently Asked Questions (FAQ)

Common questions about Альфацет (FAQ)


Q: How quickly should I expect to feel the effects of Альфацет?

A: According to official pharmacokinetic information, the drug is rapidly absorbed. For the Immediate-Release (IR) forms, the highest concentrations in the bloodstream are typically reached within 30 to 60 minutes after administration. The Extended-Release (ER) tablets take slightly longer, reaching their peak concentration around 2.5 hours.


Q: Does Альфацет cure the condition or just manage the symptoms?

A: Альфацет is an antibiotic, and its function is bactericidal, meaning it works by actively killing susceptible bacteria. Its purpose is to eliminate the microorganisms causing the infection, rather than simply managing the symptoms.


Q: Can Альфацет cause stomach upset or digestive issues?

A: Official adverse reaction reports indicate that gastrointestinal issues are common side effects. Patients often report symptoms such as diarrhea and stomach cramps. Nausea and vomiting are also reported, though less frequently.


Q: Is it normal to feel tired or drowsy after taking Альфацет?

A: Drowsiness (somnolence) and dizziness are central nervous system (CNS) effects that have been reported, although rarely. These effects are listed in regulatory sources, but a definite link to the medication is not always established.


Q: Are there any long-term side effects associated with regular use of Альфацет?

A: Regulatory documents state that prolonged use of antibiotics may lead to the overgrowth of non-susceptible organisms, which can cause a new infection (superinfection). Data regarding the effects of using the medication for several years are often limited.


Q: Does Альфацет interact with common cold or flu medications?

A: This drug is known to interact with various medicines, including certain components often found in cold and flu remedies, such as some antihistamines or anti-inflammatory drugs. Official drug labels advise that all concurrent medications should be disclosed to a healthcare provider for review.


Q: What happens if I miss a scheduled dose of Альфацет?

A: The regulatory guidance notes that adhering to the full treatment course as directed is critical. Skipping doses or failing to complete the full course may decrease the effectiveness of the treatment. Failure to complete the course can also contribute to the development of drug-resistant bacteria.


Q: Is Альфацет suitable for older adults (seniors)?

A: The use of Альфацет in older adults requires caution primarily because age-related decreases in kidney function (renal function) may affect how the drug is cleared from the body. Careful observation and monitoring by a healthcare provider may be necessary.


Q: Does Альфацет affect blood pressure or heart rate?

A: Rare cardiovascular side effects, such as low blood pressure (hypotension) and palpitations (an abnormal heartbeat), have been reported. A definite link between the medication and these specific cardiac events has not been established.


Q: Is there a generic version of Альфацет available?

A: Yes, the active ingredient, Cefaclor, is widely available in generic formulations. These generic products are reviewed by regulatory bodies and are considered therapeutically equivalent to the original brand-name medication.


Q: Why is Альфацет sometimes prescribed along with other drugs?

A: Antibiotics may be used in combination with other treatments in specific clinical situations, such as addressing complex or mixed infections. The decision to use this medicine alongside other treatments is based on a clinical assessment by a healthcare provider.


Q: Can Альфацет affect my ability to drive or operate machinery?

A: Reported central nervous system effects, although rare, include dizziness and drowsiness (somnolence). Because these symptoms can potentially affect attention and coordination, they may impair a person's ability to safely operate machinery or drive.


Q: What research or studies back up the effectiveness of Альфацет?

A: The effectiveness of this medicine is supported by clinical trials. These studies demonstrate its activity against susceptible strains of bacteria in various approved uses, such as respiratory tract infections, skin infections, and urinary tract infections.


Q: Is it normal if my urine changes color after taking Альфацет?

A: While the product label does not explicitly report urine discoloration as a side effect, the medicine is known to interfere with certain urine glucose tests (such as Benedict's or Clinitest), sometimes causing a false-positive result. This indicates a measurable interaction with urine components.


Q: Can I crush or split the Альфацет tablet if it's hard to swallow?

A: Official instructions for administration strictly state that tablets and capsules must be swallowed whole and should not be crushed, cut, or chewed. If swallowing the solid dosage forms is challenging, the oral suspension formulation is an alternative option that exists.


Q: What should I do if I suspect an allergic reaction to Альфацет?

A: If there is any suspicion of an allergic or hypersensitivity reaction, official regulatory information states that the drug should be discontinued immediately. Severe acute reactions are noted to require appropriate emergency measures.


Q: Can Альфацет be taken on an empty stomach?

A: The requirement depends on the formulation used. Immediate-Release (IR) forms, like capsules and suspensions, can be taken with or without food. However, the Extended-Release (ER) tablets must be taken with a meal for proper absorption.


Q: Is Альфацет addictive or habit-forming?

A: No, Альфацет (Cefaclor) is classified as an antibiotic. Regulatory labeling contains no indication that this medicine possesses any addictive or habit-forming properties.


Q: Does Альфацет interact with herbal remedies like St. John's Wort?

A: Official product information notes that all concurrent products being used, including herbal remedies, should be discussed with a healthcare provider to assess for potential interactions.


Q: Can people with kidney problems safely use Альфацет?

A: The use of this medicine requires caution in patients with markedly impaired renal function. Careful clinical observation and monitoring by a healthcare provider are necessary for patients with impaired renal function.


Q: What are the signs that Альфацет is actually working?

A: Patients are generally expected to begin feeling better or see improvement in symptoms early on in the course of therapy. The full course of medication is intended to be completed as directed, even if symptoms improve quickly, to fully eliminate the infection.


Q: Is the effectiveness of Альфацет reduced by certain foods?

A: For the Immediate-Release (IR) formulations, taking the drug with food may slightly reduce the peak concentration in the bloodstream, though total absorption remains the same. The Extended-Release (ER) tablets are specifically designed to be taken with food to optimize their effectiveness.


Q: Does Альфацет have a 'peak' time in the bloodstream?

A: Yes, regulatory pharmacokinetic data confirm a peak time ( T max). This is typically between 30 and 60 minutes for IR formulations, and approximately 2.5 hours for the ER tablets.


Q: Are headaches a common side effect of Альфацет?

A: Yes, regulatory documentation specifically lists headache as a commonly reported side effect, particularly in studies involving the Extended-Release (ER) tablet formulation.


Q: Why is it important to check for interactions before starting Альфацет?

A: It is important because the medicine has documented interactions that can affect safety. For instance, it can increase the risk of bleeding when taken with blood thinners like Warfarin, and certain antacids can reduce the amount of the drug absorbed by the body.


Q: Can Альфацет cause changes in mood or anxiety levels?

A: Rare central nervous system effects that have been reported include agitation, nervousness, insomnia, and confusion. These symptoms could potentially affect a person's mood or anxiety levels, but a definite link between the medication and these specific effects has not been established.


Q: How soon after stopping Альфацет will it be completely out of my system?

A: The drug is eliminated rapidly from the body. In individuals with healthy kidney function, the serum half-life is very short, typically ranging from 0.6 to 0.9 hours. Most of the medicine is excreted unchanged in the urine within approximately eight hours of administration.


Q: Can I take Альфацет if I'm already taking a multivitamin or supplements?

A: Official product information notes that all medicines, vitamins, and supplements being used should be discussed with a healthcare provider to assess for potential interactions.


Q: Can pregnant or breastfeeding women use Альфацет?

A: The medicine is classified as Pregnancy Category B. Regulatory documents state that use during pregnancy is allowed only if clearly needed. As the drug is found in human milk in trace amounts, caution is noted for nursing women.


Q: Can people with chronic conditions like diabetes use Альфацет?

A: The medicine is documented to interfere with certain urine glucose tests, such as Benedict's, Fehling's, and Clinitest. This may cause a false-positive result, which is a consideration for people managing diabetes.


Q: Is there any research on Альфацет's effect on sleep quality?

A: Insomnia, or difficulty sleeping, is documented in the adverse reaction reports as a rare central nervous system side effect of uncertain causal relationship.


Q: Are there any reported interactions between Альфацет and common allergy medicines?

A: Some moderate interactions have been reported between Cefaclor and specific common allergy medications, such as certain antihistamines. As with any potential combination, discussion with a healthcare provider is necessary before using these medicines together.


Q: What kind of studies have been done on Альфацет's long-term safety?

A: Regulatory reports indicate that studies have not been performed to definitively determine the potential for carcinogenicity (the ability to cause cancer) or impairment of fertility. Safety studies focus primarily on the approved, short-term treatment duration.

How should Альфацет be stored and disposed of?

Storage Requirements by Dosage Form

The official storage conditions for Альфацет (Cefaclor) differ based on the product form. Solid dosage forms, including capsules, tablets, and the dry powder, must be stored at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). These forms must be kept in the original, tightly closed container and protected from excess moisture and heat.

Once the powder is mixed, the reconstituted oral suspension must be stored in a refrigerator, between 2 C and 8 C. This suspension must not be frozen and must be discarded after 14 days from the date of preparation.

Disposal and Safety

All medicine must be kept out of the sight and reach of children. Unused or expired product should be disposed of in accordance with local regulations, often by returning it to a pharmacy or drug take-back location.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Альфацет found in:

A-Z Index: